A blood test to find tumor DNA in adults with high‑risk or advanced germ‑cell tumors

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a specimen collection protocol that takes whole blood to look for circulating tumor DNA (ctDNA) in adults with high‑risk stage I, clinical stage II, or clinical stage III/IS germ‑cell tumors. Participants must have histologic or serologic confirmation of seminomatous or non‑seminomatous germ‑cell tumor and available archival tumor tissue. Blood samples will be processed for ctDNA analysis in collaboration with a commercial partner, and results will be compared with clinical and pathologic data to develop a post‑treatment detection tool. The study is conducted at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. ≥ 18 years old at the time of informed consent
2. Ability to provide written informed consent and HIPAA authorization
3. Subjects must have histologically or serologically confirmed seminomatous or non seminomatous germ cell tumor. Non-seminoma includes embryonal carcinoma, choriocarcinoma, yolk sac tumor, or teratoma.

   Note: Cohort I is for high-risk clinical stage I disease (high risk will be defined as per enrolling investigator discretion). Cohort II is for clinical stage II. Cohort III is for clinical stage III or IS.
4. Archival tissue for germ-cell tumor diagnosis available

Exclusion Criteria:

1. Concurrent disease or condition that would make the subject inappropriate for study participation
2. Any serious medical disorder that would interfere with the subject's safety
3. Dementia, altered mental status, or any psychiatric condition that would prohibit the understanding or rendering of informed consent per treating physician coverage.
4. Patient is being tested for minimal residual disease with other experimental platforms

Where it's running

• Indiana University Melvin and Bren Simon Comprehensive Cancer Center
  Indianapolis, Indiana, United States Recruiting

Study contacts

• Principal investigator: Nabil Adra, MD — Indiana University
• Study coordinator: Marietta Moore, RN
• Email: marlmoor@iu.edu
• Phone: 317-274-7477

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Paclitaxel-Bleomycin/Etoposide/Cisplatin vs BEP in poor-prognosis NSGCT with unfavorable tumor marker decline

  This trial tests whether adding paclitaxel to BEP improves outcomes for patients with poor-prognosis non-seminomatous germ cell tumors who have unfavorable declines in tumor markers after initial BEP.

  Recruiting Phase 2 Blokhin's Russian Cancer Research Center · Moscow · NCT07847190

• Using Ivocizumab to treat various advanced rare tumors

  This study is testing if a new treatment called Ivocizumab can help people with different types of advanced rare tumors feel better and live longer.

  Recruiting Phase 2 Fudan University · Shanghai, Shanghai Municipality · NCT06683846

• Add Pedmark to cisplatin chemotherapy to prevent hearing loss in men with stage II–III metastatic testicular germ cell tumors

  We will test whether adding Pedmark to cisplatin chemotherapy reduces hearing damage in men with stage II–III metastatic testicular germ cell tumors.

  Recruiting Phase 1 City of Hope Medical Center · Duarte, California · NCT07218913

• Measuring bile acids in blood and tumor tissue to help detect and predict treatment response in testicular germ cell tumors

  This project will measure bile acids and related signals in blood and tumor tissue to see if they can help detect disease and predict chemotherapy response in adult men with testicular germ cell tumors.

  Recruiting University Hospital, Clermont-Ferrand · Clermont-Ferrand · NCT07463508

• Using microRNA to improve testicular cancer management

  This study is testing if a specific microRNA can help doctors better detect and manage testicular cancer by identifying active tumor cells in patients.

  Recruiting at 4 sites Haukeland University Hospital · Bergen and 5 other locations · NCT04914026

• B7-H3 CAR T-cell therapy for pediatric solid tumors

  This study is testing a new type of immune therapy using specially modified T cells to see if it can help children with tough-to-treat solid tumors.

  Recruiting Phase 1 St. Jude Children's Research Hospital · Memphis, Tennessee · NCT04897321

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.